Group 1 - The core viewpoint of the report is that Bank of America Securities has raised the target price for CSPC Pharmaceutical Group (01093) from HKD 8.5 to HKD 9.1, while maintaining a "Underperform" rating due to sales pressure on the existing product portfolio and limited short-term contributions from the R&D pipeline [1] - The report highlights a collaboration agreement between CSPC and AstraZeneca to develop innovative long-acting peptide drugs, with a total agreement value of up to USD 18.5 billion [1] - Under the agreement, CSPC will receive an upfront payment of USD 1.2 billion and is eligible for up to USD 3.5 billion in potential R&D milestone payments, as well as up to USD 13.8 billion in potential sales milestone payments [1] Group 2 - The report indicates that CSPC announced three potential out-licensing transactions last May, and this agreement is the second transaction to be realized, although the realization has been delayed compared to expectations [1] - Due to the assets in the agreement being in the early stages, the report does not include related revenue in its forecasts, only accounting for the upfront payment, while raising the revenue and net profit forecasts for 2026 by 27.9% and 107.2%, respectively [1]
美银证券：升石药集团目标价至9.1港元 重申“跑输大市”评级